THIRD AMENDMENT TO COMPOUND LICENSE AGREEMENT FOR APG-1197Compound License Agreement • July 1st, 2020 • Unity Biotechnology, Inc. • Pharmaceutical preparations
This third amendment (the “Third Amendment”) to the Compound License Agreement for APG1197 dated January 2, 2019 (the “Original License Agreement”) is made by and between Ascentage Pharma Group Corp. Ltd., a Hong Kong corporation (“Ascentage”), with a business address at 9/F, Wah Yuen Building 149 Queen’s Road , Central Hong Kong, and Unity Biotechnology, Inc., a Delaware corporation (“Unity”), with a business address at 285 East Grand Avenue, South San Francisco, California 94080 effective as of June 29, 2020 (the “Third Amendment Effective Date”). Ascentage and Unity are sometimes referred to herein as individually as a “Party” and collectively as the “Parties”. Defined terms used herein and not otherwise defined shall have the meanings set forth in the Original License Agreement.
